Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1972 1
1976 2
1978 1
1979 1
1982 1
1984 3
1985 3
1986 2
1988 3
1990 2
1991 3
1992 5
1993 2
1994 5
1995 3
1996 3
1998 5
1999 5
2000 8
2001 9
2002 10
2003 20
2004 17
2005 27
2006 22
2007 17
2008 31
2009 31
2010 28
2011 34
2012 46
2013 40
2014 39
2015 38
2016 38
2017 39
2018 39
2019 25
2020 31
2021 35
2022 36
2023 49
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

716 results

Results by year

Filters applied: . Clear all
Page 1
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Mato AR, et al. Among authors: tsai de. Lancet. 2021 Mar 6;397(10277):892-901. doi: 10.1016/S0140-6736(21)00224-5. Lancet. 2021. PMID: 33676628 Clinical Trial.
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
Wang E, Mi X, Thompson MC, Montoya S, Notti RQ, Afaghani J, Durham BH, Penson A, Witkowski MT, Lu SX, Bourcier J, Hogg SJ, Erickson C, Cui D, Cho H, Singer M, Totiger TM, Chaudhry S, Geyer M, Alencar A, Linley AJ, Palomba ML, Coombs CC, Park JH, Zelenetz A, Roeker L, Rosendahl M, Tsai DE, Ebata K, Brandhuber B, Hyman DM, Aifantis I, Mato A, Taylor J, Abdel-Wahab O. Wang E, et al. Among authors: tsai de. N Engl J Med. 2022 Feb 24;386(8):735-743. doi: 10.1056/NEJMoa2114110. N Engl J Med. 2022. PMID: 35196427 Free PMC article.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, Shah NN, Coombs CC, Ujjani CS, Fakhri B, Cheah CY, Patel MR, Alencar AJ, Cohen JB, Gerson JN, Flinn IW, Ma S, Jagadeesh D, Rhodes JM, Hernandez-Ilizaliturri F, Zinzani PL, Seymour JF, Balbas M, Nair B, Abada P, Wang C, Ruppert AS, Wang D, Tsai DE, Wierda WG, Jurczak W. Mato AR, et al. Among authors: tsai de. N Engl J Med. 2023 Jul 6;389(1):33-44. doi: 10.1056/NEJMoa2300696. N Engl J Med. 2023. PMID: 37407001 Clinical Trial.
Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma.
Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN. Wang ML, et al. Among authors: tsai de. J Clin Oncol. 2023 Aug 20;41(24):3988-3997. doi: 10.1200/JCO.23.00562. Epub 2023 May 16. J Clin Oncol. 2023. PMID: 37192437 Free PMC article.
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.
Montoya S, Bourcier J, Noviski M, Lu H, Thompson MC, Chirino A, Jahn J, Sondhi AK, Gajewski S, Tan YSM, Yung S, Urban A, Wang E, Han C, Mi X, Kim WJ, Sievers Q, Auger P, Bousquet H, Brathaban N, Bravo B, Gessner M, Guiducci C, Iuliano JN, Kane T, Mukerji R, Reddy PJ, Powers J, Sanchez Garcia de Los Rios M, Ye J, Barrientos Risso C, Tsai D, Pardo G, Notti RQ, Pardo A, Affer M, Nawaratne V, Totiger TM, Pena-Velasquez C, Rhodes JM, Zelenetz AD, Alencar A, Roeker LE, Mehta S, Garippa R, Linley A, Soni RK, Skånland SS, Brown RJ, Mato AR, Hansen GM, Abdel-Wahab O, Taylor J. Montoya S, et al. Among authors: tsai d. Science. 2024 Feb 2;383(6682):eadi5798. doi: 10.1126/science.adi5798. Epub 2024 Feb 2. Science. 2024. PMID: 38301010
Artificial Intelligence in Meta-optics.
Chen MK, Liu X, Sun Y, Tsai DP. Chen MK, et al. Among authors: tsai dp. Chem Rev. 2022 Oct 12;122(19):15356-15413. doi: 10.1021/acs.chemrev.2c00012. Epub 2022 Jun 24. Chem Rev. 2022. PMID: 35750326 Free PMC article. Review.
Plasmonic photocatalysis.
Zhang X, Chen YL, Liu RS, Tsai DP. Zhang X, et al. Among authors: tsai dp. Rep Prog Phys. 2013 Apr;76(4):046401. doi: 10.1088/0034-4885/76/4/046401. Epub 2013 Mar 4. Rep Prog Phys. 2013. PMID: 23455654 Review.
Metasurface Micro/Nano-Optical Sensors: Principles and Applications.
Qin J, Jiang S, Wang Z, Cheng X, Li B, Shi Y, Tsai DP, Liu AQ, Huang W, Zhu W. Qin J, et al. Among authors: tsai dp. ACS Nano. 2022 Aug 23;16(8):11598-11618. doi: 10.1021/acsnano.2c03310. Epub 2022 Aug 12. ACS Nano. 2022. PMID: 35960685 Review.
Vacuum ultraviolet nonlinear metalens.
Tseng ML, Semmlinger M, Zhang M, Arndt C, Huang TT, Yang J, Kuo HY, Su VC, Chen MK, Chu CH, Cerjan B, Tsai DP, Nordlander P, Halas NJ. Tseng ML, et al. Among authors: tsai dp. Sci Adv. 2022 Apr 22;8(16):eabn5644. doi: 10.1126/sciadv.abn5644. Epub 2022 Apr 20. Sci Adv. 2022. PMID: 35442736 Free PMC article.
716 results